Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis

Taylor and Francis Group, Expert Opinion on Drug Metabolism and Toxicology, 10(17), p. 1237-1243, 2021

Journal article published in 2021 by Alessandro Rizzo, Sara Merler

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by